Baxter BioPharma to provide fill/finish services for Moderna vaccine

By The Science Advisory Board staff writers

March 8, 2021 -- Baxter BioPharma has entered into an agreement with Moderna to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 vaccine in 2021.

Baxter is a contract manufacturing organization that specializes in parenteral (injected) pharmaceuticals, including vaccines. The manufacturing of Moderna's messenger RNA (mRNA)-based vaccine will take place at Baxter's fill/finish sterile manufacturing facilities located in Bloomington, IN. The site has capabilities and expertise in injectable delivery systems and clinical and commercial vaccine manufacturing.

Financial details of the agreement were not disclosed.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here